FENC
Fennec Pharmaceuticals Inc.
FENC's fundamentals are strong: revenue grew 71% and its operating margin went from −12% to 5.6%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
FENC Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Healthy | |
| Unavailable |
FENC's revenue, profitability and cash flow are currently healthy. There isn't enough data to rate its balance sheet.
FENC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 16x | $10.90 | — |
| Current | 1,090x | $10.90 | — |
| Cheap | N/A | N/A | N/A |
| Fair | N/A | N/A | N/A |
| Expensive | N/A | N/A | N/A |
Historical ranges are pointers, not guarantees.
FENC's PE is 1090x, but its earnings don't support one, so it isn't a reliable read right now.
FENC Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for FENC, with profitability improving. However, they disagree widely on these estimates.
FENC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.68 | +6660% |
| Q3 2026 | $0.01 | +$0.25 |
| Q2 2026 | -$0.13 | +$0.30 |
| Q1 2026 | -$0.29 | +$0.23 |
| Q4 2025 | -$0.34 | -$0.27 |
| Q3 2025 | -$0.24 | +$0.83 |
| Q2 2025 | -$0.43 | +$0.50 |
| Q1 2025 | -$0.52 | +$0.42 |
| Q4 2024 | -$0.07 | +$1.51 |
FENC has returned to profit: it earned $0.01 per share over the past year, after losing money the year before.
FENC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $19.6M | +57% |
| Q2 2026 | $17.9M | +85% |
| Q1 2026 | $15.1M | +73% |
| Q4 2025 | $13.8M | +74% |
| Q3 2025 | $12.5M | +79% |
| Q2 2025 | $9.7M | +33% |
| Q1 2025 | $8.8M | -66% |
| Q4 2024 | $7.9M | -20% |
FENC's revenue is recovering but still below its 2024 peak: $20M last quarter, up 57% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 24% | +25 points |
| Q2 2026 | 9.7% | +38 points |
| Q1 2026 | -0.8% | +8.4 points |
| Q4 2025 | -19% | -6.8 points |
| Q3 2025 | -1.5% | +73 points |
| Q2 2025 | -28% | +41 points |
| Q1 2025 | -9.2% | -63 points |
| Q4 2024 | -12% | +6.5 points |
FENC's operating margin was 24% last quarter, up 25 points from the same quarter a year ago.
FENC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $6.7M | +348% |
| Q2 2026 | $50K | +$3.7M |
| Q1 2026 | $2.4M | +$6.7M |
| Q4 2025 | -$6M | -$4.5M |
| Q3 2025 | $1.5M | +$3.7M |
| Q2 2025 | -$3.7M | +$4.7M |
| Q1 2025 | -$4.3M | -111% |
| Q4 2024 | -$1.5M | +$3.4M |
FENC's free cash flow has turned positive after six years mostly in the red: $3M over the past year.
FENC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.5% | +1.6M shares |
| 1 year | +37% | +10.2M shares |
| 3 years | +43% | +11.5M shares |
| 5 years | +46% | +12.1M shares |
| Available history | +91% | +18.2M shares |
FENC has 38M diluted shares, up 37% from a year ago.
FENC Net Leverage
FENC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 55.6 | Neutral |
| Stochastic | 26.3 | Neutral |
FENC's weekly RSI is 56 (neutral) and its Stochastic is 26 (neutral).
FENC PE vs Healthcare Sector
FENC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.3 | 5.6% above |
| 20 week MA | $10.7 | 1.6% above |
| 50 week MA | $9.05 | 20% above |
| 100 week MA | $8.25 | 32% above |
| 200 week MA | $8.06 | 35% above |
FENC is in an uptrend: it's above all five of its weekly moving averages, and 35% above its 200-week average.
FENC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $6.23 | $7.16 | +15% |
| 2021 | $7.16 | $4.49 | -37% |
| 2022 | $4.49 | $9.78 | +118% |
| 2023 | $9.78 | $11.2 | +15% |
| 2024 | $11.2 | $6.22 | -45% |
| 2025 | $6.22 | $8.09 | +30% |
| 2026 YTD | $8.09 | $10.9 | +35% |
FENC's yearly returns have swung widely, from +118% in 2022 to −45% in 2024. It's up 35% so far in 2026.